Syndax Pharmaceuticals (SNDX) Competitors

$20.55 -0.34 (-1.63%)

As of 04:00 PM Eastern

SNDX vs. KYMR, QGEN, ACLX, TGTX, and MIRM

Should you buy Syndax Pharmaceuticals stock or one of its competitors? MarketBeat compares Syndax Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Syndax Pharmaceuticals include Kymera Therapeutics (KYMR), Qiagen (QGEN), Arcellx (ACLX), TG Therapeutics (TGTX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Syndax Pharmaceuticals compare to Kymera Therapeutics?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Syndax Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market.

In the previous week, Kymera Therapeutics had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Kymera Therapeutics and 6 mentions for Syndax Pharmaceuticals. Kymera Therapeutics' average media sentiment score of 0.32 beat Syndax Pharmaceuticals' score of 0.05 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Syndax Pharmaceuticals has a net margin of -111.88% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Syndax Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$217.17M	8.38	-$285.42M	-$2.79	N/A
Kymera Therapeutics	$51.48M	135.03	-$311.35M	-$3.57	N/A

Syndax Pharmaceuticals currently has a consensus target price of $42.55, indicating a potential upside of 107.03%. Kymera Therapeutics has a consensus target price of $118.10, indicating a potential upside of 39.76%. Given Syndax Pharmaceuticals' higher probable upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Kymera Therapeutics beats Syndax Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Qiagen?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Qiagen has a net margin of 19.16% compared to Syndax Pharmaceuticals' net margin of -111.88%. Qiagen's return on equity of 14.40% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Qiagen	19.16%	14.40%	8.40%

Syndax Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

70.0% of Qiagen shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Qiagen has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$217.17M	8.38	-$285.42M	-$2.79	N/A
Qiagen	$2.10B	3.27	$424.88M	$1.91	17.44

Syndax Pharmaceuticals currently has a consensus target price of $42.55, indicating a potential upside of 107.03%. Qiagen has a consensus target price of $46.38, indicating a potential upside of 39.25%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Qiagen had 8 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 14 mentions for Qiagen and 6 mentions for Syndax Pharmaceuticals. Qiagen's average media sentiment score of 0.23 beat Syndax Pharmaceuticals' score of 0.05 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Qiagen beats Syndax Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Arcellx?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Arcellx has lower revenue, but higher earnings than Syndax Pharmaceuticals. Arcellx is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$217.17M	8.38	-$285.42M	-$2.79	N/A
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A

In the previous week, Syndax Pharmaceuticals had 6 more articles in the media than Arcellx. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Syndax Pharmaceuticals' score of 0.05 indicating that Arcellx is being referred to more favorably in the news media.

Company	Overall Sentiment
Syndax Pharmaceuticals	Neutral
Arcellx	Positive

96.0% of Arcellx shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Syndax Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Arcellx has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Syndax Pharmaceuticals currently has a consensus target price of $42.55, indicating a potential upside of 107.03%. Arcellx has a consensus target price of $111.87, indicating a potential downside of 2.78%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11

Syndax Pharmaceuticals has a net margin of -111.88% compared to Arcellx's net margin of -1,027.26%. Arcellx's return on equity of -55.42% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Arcellx	-1,027.26%	-55.42%	-36.24%

Summary

Syndax Pharmaceuticals beats Arcellx on 9 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to TG Therapeutics?

Syndax Pharmaceuticals (NASDAQ:SNDX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

In the previous week, TG Therapeutics had 7 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 13 mentions for TG Therapeutics and 6 mentions for Syndax Pharmaceuticals. TG Therapeutics' average media sentiment score of 0.70 beat Syndax Pharmaceuticals' score of 0.05 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals currently has a consensus target price of $42.55, indicating a potential upside of 107.03%. TG Therapeutics has a consensus target price of $52.50, indicating a potential upside of 28.71%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

58.6% of TG Therapeutics shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Syndax Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Syndax Pharmaceuticals' net margin of -111.88%. TG Therapeutics' return on equity of 88.73% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$217.17M	8.38	-$285.42M	-$2.79	N/A
TG Therapeutics	$700.35M	8.92	$447.18M	$2.86	14.26

Summary

TG Therapeutics beats Syndax Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

In the previous week, Mirum Pharmaceuticals had 18 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 24 mentions for Mirum Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.67 beat Syndax Pharmaceuticals' score of 0.05 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Syndax Pharmaceuticals currently has a consensus target price of $42.55, indicating a potential upside of 107.03%. Mirum Pharmaceuticals has a consensus target price of $136.42, indicating a potential upside of 22.47%. Given Syndax Pharmaceuticals' higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Syndax Pharmaceuticals has a net margin of -111.88% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Mirum Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$217.17M	8.38	-$285.42M	-$2.79	N/A
Mirum Pharmaceuticals	$569.61M	11.93	-$23.36M	-$13.61	N/A

Summary

Mirum Pharmaceuticals beats Syndax Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNDX vs. The Competition

Export

Metric	Syndax Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.82B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-7.37	18.98	20.89	25.59
Price / Sales	8.38	180.83	523.74	63.24
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	43.72	6.74	9.86	6.70
Net Income	-$285.42M	$24.11M	$3.55B	$333.77M
7 Day Performance	0.05%	0.08%	-0.33%	0.45%
1 Month Performance	-15.88%	0.84%	1.34%	4.06%
1 Year Performance	121.44%	78.10%	41.10%	36.24%

Syndax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNDX Syndax Pharmaceuticals	2.9485 of 5 stars	$20.55 -1.6%	$42.55 +107.0%	+105.0%	$1.82B	$217.17M	N/A	110	Analyst Forecast
KYMR Kymera Therapeutics	2.3817 of 5 stars	$86.00 +1.6%	$118.10 +37.3%	+174.9%	$7.08B	$39.21M	N/A	170	Insider Trade
QGEN Qiagen	4.567 of 5 stars	$33.04 -1.4%	$46.38 +40.4%	-26.1%	$6.81B	$2.09B	17.26	5,654	Earnings Report Dividend Increase Analyst Downgrade
ACLX Arcellx	2.4964 of 5 stars	$115.07 flat	$111.87 -2.8%	+97.5%	$6.73B	$22.29M	N/A	80	Positive News High Trading Volume
TGTX TG Therapeutics	4.2962 of 5 stars	$42.87 -0.4%	$52.50 +22.5%	+27.8%	$6.59B	$700.35M	15.05	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNDX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. KYMR, QGEN, ACLX, TGTX, and MIRM

How does Syndax Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does Syndax Pharmaceuticals compare to Qiagen?

Summary

How does Syndax Pharmaceuticals compare to Arcellx?

Summary

How does Syndax Pharmaceuticals compare to TG Therapeutics?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. KYMR, QGEN, ACLX, TGTX, and MIRM

How does Syndax Pharmaceuticals compare to Kymera Therapeutics?

Which has more risk and volatility, SNDX or KYMR?

Does the media refer more to SNDX or KYMR?

Is SNDX or KYMR more profitable?

Which has better valuation and earnings, SNDX or KYMR?

Do analysts prefer SNDX or KYMR?

Summary

How does Syndax Pharmaceuticals compare to Qiagen?

Is SNDX or QGEN more profitable?

Which has more volatility and risk, SNDX or QGEN?

Do institutionals & insiders believe in SNDX or QGEN?

Which has higher valuation and earnings, SNDX or QGEN?

Do analysts prefer SNDX or QGEN?

Does the media prefer SNDX or QGEN?

Summary

How does Syndax Pharmaceuticals compare to Arcellx?

Which has better earnings & valuation, SNDX or ACLX?

Does the media favor SNDX or ACLX?

Do insiders and institutionals have more ownership in SNDX or ACLX?

Which has more volatility and risk, SNDX or ACLX?

Do analysts recommend SNDX or ACLX?

Is SNDX or ACLX more profitable?

Summary

How does Syndax Pharmaceuticals compare to TG Therapeutics?

Does the media prefer SNDX or TGTX?

Do analysts recommend SNDX or TGTX?

Do institutionals & insiders have more ownership in SNDX or TGTX?

Which has more volatility & risk, SNDX or TGTX?

Is SNDX or TGTX more profitable?

Which has better valuation & earnings, SNDX or TGTX?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Does the media prefer SNDX or MIRM?

Which has more volatility & risk, SNDX or MIRM?

Do analysts recommend SNDX or MIRM?

Is SNDX or MIRM more profitable?

Which has better valuation & earnings, SNDX or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools